Niva Bupa Health Insurance - FY2026 Earnings Analysis

Performance Highlights

Niva Bupa reported FY2026 Gross Written Premium of ₹9,432.9 crore (without 1/n), a 27.4% year-on-year increase, meaningfully ahead of the health insurance industry's 16.7% growth, while IFRS Profit After Tax of ₹366.1 crore nearly doubled from ₹202.9 crore in FY2025. Q4 FY2026 alone delivered ₹3,123.4 crore in GWP, up 30.4% year-on-year, with quarterly PAT of ₹157.8 crore representing 89.3% growth. The Combined Insurance Service Ratio improved 160 basis points to 101.4%, driven by an Expense Ratio reduction from 39.2% to 36.5%, even as the Claims Ratio edged up from 63.8% to 64.9% under IFRS.

Retail Health GWP, the company's core earnings engine, grew 35.0% to ₹6,581.5 crore (without 1/n), lifting retail market share to 10.1% from 9.4%, with retail accretion market share reaching 14.0%. Active lives insured expanded to 25.2 million, and the renewal rate for retail health indemnity improved to 92.8%, reflecting strengthening customer retention. Distribution scale advanced materially, with individual agents growing by 58,000 to 238,517 and the Preferred Partner Network hospital count reaching 1,116 across 49 cities, supporting claims cost discipline.

Management Outlook and Forward Catalysts

Management has signalled a continued push toward profitable scale, with the Expense of Management ratio declining sharply to 33.7% of GWP on a 1/n basis and Return on Average Net Worth rising to 10.7% from 7.4% — indicating the business is entering a more capital-efficient phase. The company's AUM grew to ₹9,669.7 crore with an investment yield of 7.2%, and the pending transition to Ind AS reporting from April 1, 2026 is expected to further improve disclosure transparency and align the company with global insurance reporting standards.

The central investor debate heading into FY2027 centres on whether Niva Bupa can sustain its market share gains while bringing the CISR below 100% — a threshold that would signal true underwriting profitability. Bulls will watch for continued expense ratio compression, resolution of the IRDAI Expenses of Management forbearance matter from FY2025, and accretion market share holding above 14%; bears will focus on the rising retail claims ratio of 66.8% and medical cost inflation running at a 7.2% five-year CAGR on the claims cost index.